UNSPSC 51281811: Detorubicin

This classification denotes an anthracycline antibiotic with the molecular formula C33H39NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822EC3XEJZ, chemically known as glyoxylic acid 3(sup 2)-ester with doxorubicin, 2-(diethyl acetal) but generally known as detorubicin, which bears US NIH Compound Identifier 114806. European Medicines Agency schedules Detorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07013MIG.

UNSPSC 51281811 Detorubicin is a Commodity code that state and local procurement offices nominally use for chemotherapy agents, but recent opportunities show little activity directly aligned with this specific pharmaceutical. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic pharmaceuticals (Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets) rather than oncology products. Seminole County, Florida, posted an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building—a public-health pharmaceutical procurement unrelated to detorubicin's chemotherapy focus. State and local buyers using this code appear to include county health departments and state health agencies executing pharmaceutical warehouse and emergency-response procurement through cooperative purchasing vehicles and competitive bidding. The code shows minimal recent activity specifically for detorubicin or oncology pharmaceutical supply.

The geographic spread of recent opportunities spans Florida and Illinois, with Illinois securing a high-value multiyear pharmaceutical supply award through a statewide cooperative. Neither opportunity lists a response date current to the present day—the Seminole County IFB due date of July 26, 2023, is historical—indicating limited recent open solicitation activity under this code. Buyers deploying this code appear to favor consolidated cooperative purchasing agreements and piggyback vehicles to source bulk pharmaceutical inventory. The mismatch between the code's nominal scope (detorubicin, a specific oncology agent) and the actual pharmaceutical categories being purchased (antibiotics, emergency-response drugs, deactivation systems) suggests that state and local offices may be tagging broader pharmaceutical procurement with this code or that detorubicin demand is not currently generating visible solicitations in the sampled data.